NIH and Pentagon sign agreement for $2B in biodefense research

The National Institutes of Health (NIH) and the Department of Defense have signed an interagency agreement to facilitate the transfer of funding for the research and development of medical countermeasures. The agreement, established under the Economy Act, aims to support advanced development against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases.

Reports indicate that as much as $2 billion from the National Institute of Allergy and Infectious Diseases (NIAID)—approximately one-third of its budget—could be involved in this 10-year arrangement. The deal allows the NIH to utilize the Department of Defense's procurement and grant-making infrastructure to move early-stage scientific findings toward field-ready therapeutics, diagnostics, and personal protective equipment.

While officials state the move is intended to “untangle civilian public-health initiatives from defence priorities” and reallocate “Department of War-related” research to the appropriate agency, concerns have been raised regarding transparency. Critics note that routing infectious-disease projects through Pentagon funding channels could obscure the ultimate recipients and purposes of federal spending, potentially complicating future investigations into the origins of pandemics.